Switch to: References

Add citations

You must login to add citations.
  1. Can HIV vaccines be shared fairly? Perspectives from Tanzania.Jon F. Merz, Erasto Mbugi, David Nderitu, Mangi Ezekiel & Godwin Pancras - 2022 - BMC Medical Ethics 23 (1):1–9.
    BackgroundFor over 35 years, Africa has continued to host HIV vaccine trials geared towards overturning the HIV/aids pandemic in the continent. However, the methods of sharing the vaccines, when available remain less certain. Therefore, the study aims to explore stakeholders’ perspectives in the global South, in this case, Tanzania, on how HIV vaccines ought to be fairly shared.MethodsThe study deployed a qualitative case study design. Data were collected through in-depth interviews and focus group discussions with a total of 37 purposively (...)
    Download  
     
    Export citation  
     
    Bookmark   2 citations  
  • Communities need to be equal partners in determining whether research is acceptable.Bridget G. Haire & John M. Kaldor - 2018 - Journal of Medical Ethics 44 (3):159-160.
    In many countries around the world, people who inject drugs remain at high risk of HIV acquisition not because effective forms of prevention are unknown, nor because they find effective prevention undesirable, but because those in charge, mainly politicians but also bureaucrats, find evidence-based practice politically unacceptable. The evidence for preventive efficacy of harm reduction strategies, most prominently needle and syringe programmes but also treatment programmes such as opiate substitution, is irrefutable.1 However, political responses to drug use issues are varied (...)
    Download  
     
    Export citation  
     
    Bookmark   2 citations  
  • “Reasonable Availability” Criterion Remains Salient.Bridget Gabrielle Haire - 2016 - American Journal of Bioethics 16 (6):19-21.
    Download  
     
    Export citation  
     
    Bookmark   1 citation  
  • Undue inducement, or unfair exclusion: considering a case study of pregnancy in an HIV prevention trial.Bridget G. Haire & Morenike Oluwatoyin Folayan - 2017 - Journal of Medical Ethics 43 (12):829-830.
    In their recent paper‘Undue inducement: a case study in CAPRISA 008’, Mngadi et al conclude that a participant in an HIV prevention study who deliberately concealed her pregnancy was not ‘unduly induced’ to participate by the offer of an experimental product. This paper argues that while the authors’ conclusion is sound, the framing of this case study is consistent with the preoccupation in research ethics with the concept of undue inducement, coupled with a highly risk-averse attitude to pregnancy. We suggest (...)
    Download  
     
    Export citation  
     
    Bookmark  
  • Implementing post-trial access plans for HIV prevention research.Amy Paul, Maria W. Merritt & Jeremy Sugarman - 2018 - Journal of Medical Ethics 44 (5):354-358.
    Ethics guidance increasingly recognises that researchers and sponsors have obligations to consider provisions for post-trial access to interventions that are found to be beneficial in research. Yet, there is little information regarding whether and how such plans can actually be implemented. Understanding practical experiences of developing and implementing these plans is critical to both optimising their implementation and informing conceptual work related to PTA. This viewpoint is informed by experiences with developing and implementing PTA plans for six large-scale multicentre HIV (...)
    Download  
     
    Export citation  
     
    Bookmark   2 citations  
  • Human dignity as a basis for providing post-trial access to healthcare for research participants: a South African perspective.Pamela Andanda & Jane Wathuta - 2018 - Medicine, Health Care and Philosophy 21 (1):139-155.
    This paper discusses the need to focus on the dignity of human participants as a legal and ethical basis for providing post-trial access to healthcare. Debate about post-trial benefits has mostly focused on access to products or interventions proven to be effective in clinical trials. However, such access may be modelled on a broad fair benefits framework that emphasises both collateral benefits and interventional products of research, instead of prescribed post-trial access alone. The wording of the current version of the (...)
    Download  
     
    Export citation  
     
    Bookmark   3 citations